GSK spun off its over-the-counter products business to launch Haleon, an independent entity totally focused on consumer health. The company said the newly listed business is driven by its purpose to deliver better everyday health with humanity. It noted that it will continue to develop category-leading brands that address real consumer health needs while focusing on future innovation across its entire portfolio.
Here, Rachel Marler, chief customer officer, U.S. at Haleon, shares the reasons behind making Haleon a standalone company and what’s in store for the spin-off.
Drug Store News: Why did GSK create Haleon?
Rachel Marler: GSK outlined the plan to separate back in 2018, with the strategic rationale to realize the Consumer Healthcare division’s growth potential and unlock the value inherent within the business. In establishing Haleon as an independent company as of July 18, 2022, we have created a new world leader, 100% focused on consumer health, which is an incredible opportunity for us.
At a time when consumer interest in health and wellness and proactive self-care are more top of mind than ever before, combined with an aging population, increased pressure on our healthcare systems and sizeable unmet consumer needs, the launch of Haleon as an independent, standalone company, 100% focused on consumer health, is highly significant.